Scipher Medicine is expanding beyond its rheumatoid arthritis molecular diagnostic assay to broader precision medicine efforts in immunology and other non-oncology areas. Under new leadership, the company has leveraged its large non-oncology transcriptomic dataset, made possible by extensive data-sharing partnerships with pharma and informatics firms. It recently partnered with Savant Bio to integrate clinical notes and pathology reports, enhancing the ability to link patient health data with molecular signatures. This shift mirrors successes in oncology where broad omics data drives biomarker discovery and therapeutic development. Scipher aims to spearhead precision medicine by identifying new biomarkers for therapy selection and drug discovery, addressing gaps in immunological diseases.